首页|甲状腺乳头状癌131I治疗后显像结果的临床观察

甲状腺乳头状癌131I治疗后显像结果的临床观察

扫码查看
原文链接
  • 国家科技期刊平台
  • NETL
  • NSTL
  • 万方数据
目的 分析甲状腺乳头状癌 131I治疗后的 131I全身平面显像以及SPECT/CT断层显像结果。方法 回顾性分析 2020 年 3 月至 2022 年 3 月信阳市中心医院收治甲状腺乳头状癌术后采取 131I治疗的患者共 86 例的临床资料，所有患者均在用药 131I治疗后开展 131I全身平面显像以及SPECT/CT断层显像，观察所有患者 131I治疗后的显像结果;所有患者均开展 6 个月以上随访，将活检病理或者长期随访结果作为金标准，统计并比较两种显像方法对于转移灶的诊断准确度、敏感度、特异度、阳性预测值和阴性预测值。结果 86 例患者中，131I治疗后开展 131I全身平面显像发现82 例存在异常 131I有关浓聚灶，占比是 95。35%;开展SPECT/CT断层显像发现 86 例存在异常的 131I浓聚灶，占比是100。00%，经诊断全部确诊为术后甲状腺残留;活检病理或者长期随访显示转移 36 例，未转移 50 例;131I全身平面显像发现转移 46 例，无转移 40 例;SPECT/CT断层显像发现转移 38 例，无转移 48 例。SPECT/CT断层显像对于转移灶的诊断准确度、敏感度、特异度、阳性和阴性预测值是 95。35%、97。22%、94。00%、92。11%、97。92%，高于 131I全身平面显像69。77%、77。78%、64。00%、60。87%、80。00%，差异有统计学意义(P＜0。05)。结论 和 131I全身平面显像相比，甲状腺乳头状癌 131I治疗后开展SPECT/CT断层显像能更好观察到患者 131I异常浓聚灶和明确甲状腺残留情况，同时提升对转移灶的诊断效能。
Clinical Observation of Imaging Results After Treatment of Thyroid Papillary Carcinoma 131I
Objective To analyze the results of 131I whole body plane imaging and SPECT/CT tomography after treatment of papillary thyroid carcinoma 131I.Methods The clinical data of 86 patients with papillary thyroid cancer treated with 131I after operation in Xinyang Central Hospital from March 2020 to March 2022 were retrospectively analyzed.All patients were treated with 131I whole-body imaging and SPECT/CT tomography,and the imaging results of all patients were observed after 131I treatment.All patients were followed up for more than 6 months,and the results of biopsy pathology or long-term follow-up were used as the gold standard.The diagnostic accuracy,sensitivity,specificity,positive predictive value,and negative predictive value of the two imaging methods for metastatic lesions were statistically compared.Results Among the 86 patients,82 cases of abnormal 131I-related concentration were found by 131I whole-body imaging after treatment,accounting for 95.35%.SPECT/CT imaging showed that 86 cases had abnormal 131I concentration,accounting for 100.00%.All of them were diagnosed as thyroid residual after the operation.Biopsy pathology or long-term follow-up showed metastasis in 36 cases and no metastasis in 50 cases.131I whole-body imaging showed metastasis in 46 cases and no metastasis in 40 cases.SPECT/CT imaging showed metastasis in 38 cases and no metastasis in 48 cases.The diagnostic accuracy,sensitivity,specificity,and positive and negative predictive values of SPECT/CT for metastasis were 95.35%,97.22%,94.00%,92.11%,and 97.92%,which were higher than those of 131I whole-body imaging(69.77%,77.78%,64.00%,60.87%,80.00%),the difference was statistically significant(P＜0.05).Conclusion Compared with 131I whole-body imaging,SPECT/CT imaging after treatment of papillary thyroid carcinoma 131I can better observe the abnormal concentration of 131I and determine the thyroid residual status,and improve the diagnostic efficiency of metastatic lesions.

papillary thyroid carcinoma131I treatmentSPECT/CT tomographyaccuracysensitivityspecificity

姚宇、刘江波

展开 >

信阳市中心医院 核医学科,河南 信阳 464000

河南科技大学第一附属医院 乳腺外科,河南 洛阳 471000

甲状腺乳头状癌 131I治疗 SPECT/CT断层显像 准确度 敏感度 特异度

2024

10.12385/j.issn.2096-1278(2024)02-0128-03

临床研究
西安交通大学

临床研究

影响因子：0.234
ISSN：2096-1278
年,卷(期)：2024.32(2)
  • 19